About
About Shionogi
Our leadership team
History and values
Global affiliates and locations
Investor relations
Sustainability
Sustainability
Tax strategy
Transparency
Governance, policies and position statements
Carbon reduction plan
Innovation
Innovation
Our areas of focus
Strategic partnering in Europe
Global innovation
Grants and donations
News
Investors
Careers
Contact
Europe
Worldwide
Home
News
Press Releases
2026
06
Shionogi and F2G announce positive topline results from global Phase 3 OASIS study evaluating oral olorofim versus AmBisome followed by Standard of Care in patients with invasive aspergillosis
Release
Medical News
2026/06/18
Shionogi and F2G announce positive topline results from global Phase 3 OASIS study evaluating oral olorofim versus AmBisome® followed by Standard of Care in patients with invasive aspergillosis
